Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes
Shen Dong, Kamir J. Hiam-Galvez, Cody T. Mowery, et al.
JCI Insight (2021) Vol. 6, Iss. 18
Open Access | Times Cited: 147

Showing 1-25 of 147 citing articles:

Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease – novel insights into cellular communication circuits
Moritz Peiseler, Robert F. Schwabe, Jochen Hampe, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 4, pp. 1136-1160
Open Access | Times Cited: 303
Engineering IL-2 for immunotherapy of autoimmunity and cancer
Rosmely Hernandez, Janika Põder, Kathryn M LaPorte, et al.
Nature reviews. Immunology (2022) Vol. 22, Iss. 10, pp. 614-628
Closed Access | Times Cited: 219
Strategies to therapeutically modulate cytokine action
Warren J. Leonard, Jian‐Xin Lin
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 10, pp. 827-854
Closed Access | Times Cited: 58
The role of inflammation in autoimmune disease: a therapeutic target
Yu Xiang, Mingxue Zhang, D.Y. Jiang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 53
The immunology of type 1 diabetes
Kevan C. Herold, Thomas Delong, Ana Luisa Perdigoto, et al.
Nature reviews. Immunology (2024) Vol. 24, Iss. 6, pp. 435-451
Open Access | Times Cited: 49
Opportunities for Treg cell therapy for the treatment of human disease
Jeffrey A. Bluestone, Brent S. McKenzie, Joshua Beilke, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 48
T cells and their products in diabetic kidney disease
Yue Liu, Yaodong Lv, Tingwei Zhang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 43
Immunogenicity of CRISPR therapeutics—Critical considerations for clinical translation
Radwa Ewaisha, Karen S. Anderson
Frontiers in Bioengineering and Biotechnology (2023) Vol. 11
Open Access | Times Cited: 42
IL-2-based approaches to Treg enhancement
Ffion Harris, Yoana Arroyo Berdugo, Timothy Tree
Clinical & Experimental Immunology (2022) Vol. 211, Iss. 2, pp. 149-163
Open Access | Times Cited: 67
The emerging role of regulatory cell-based therapy in autoimmune disease
Farbod Ghobadinezhad, Nasim Ebrahimi, Fatemeh Mozaffari, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 58
Immunopathogenesis and environmental triggers in coeliac disease
Anaïs Levescot, Georgia Malamut, Nadine Cerf–Bensussan
Gut (2022) Vol. 71, Iss. 11, pp. 2337-2349
Open Access | Times Cited: 55
Low dose interleukin-2 selectively expands circulating regulatory T cells but fails to promote liver allograft tolerance in humans
Tiong Yeng Lim, Elena Perpiñán, María‐Carlota Londoño, et al.
Journal of Hepatology (2022) Vol. 78, Iss. 1, pp. 153-164
Open Access | Times Cited: 47
Selective decrease of donor-reactive T regs after liver transplantation limits T reg therapy for promoting allograft tolerance in humans
Qizhi Tang, Joey Leung, Yani Peng, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 669
Closed Access | Times Cited: 44
IL-2 immunotherapy for targeting regulatory T cells in autoimmunity
Valentina Lykhopiy, Vanshika Malviya, Stéphanie Humblet‐Baron, et al.
Genes and Immunity (2023) Vol. 24, Iss. 5, pp. 248-262
Open Access | Times Cited: 30
Insulin B peptide-MHC class II-specific chimeric antigen receptor-Tregs prevent autoimmune diabetes in mice
Justin A. Spanier, Vivian Fung, Christine M. Wardell, et al.
Journal of Clinical Investigation (2023)
Open Access | Times Cited: 27
A phase 2 randomized trial with autologous polyclonal expanded regulatory T cells in children with new-onset type 1 diabetes
Christine Bender, Alice Wiedeman, Alex Hu, et al.
Science Translational Medicine (2024) Vol. 16, Iss. 746
Closed Access | Times Cited: 14
Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders
Yi Song, Jian Li, Yuzhang Wu
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 13
Genetic engineering of regulatory T cells for treatment of autoimmune disorders including type 1 diabetes
Karoliina Tuomela, Megan K. Levings
Diabetologia (2024) Vol. 67, Iss. 4, pp. 611-622
Open Access | Times Cited: 12
Emerging strategies for nanomedicine in autoimmunity
Ajay S. Thatte, Margaret M. Billingsley, Drew Weissman, et al.
Advanced Drug Delivery Reviews (2024) Vol. 207, pp. 115194-115194
Closed Access | Times Cited: 9
Interleukin-2 immunotherapy reveals human regulatory T cell subsets with distinct functional and tissue-homing characteristics
Miro E. Raeber, Dominic Caspar, Yves Zurbuchen, et al.
Immunity (2024) Vol. 57, Iss. 9, pp. 2232-2250.e10
Open Access | Times Cited: 9
Generation of tolerogenic antigen-presenting cells in vivo via the delivery of mRNA encoding PDL1 within lipid nanoparticles
Yang Liu, Jun Li, Baowen Zhang, et al.
Nature Biomedical Engineering (2025)
Closed Access | Times Cited: 1
Challenges and opportunities in achieving effective regulatory T cell therapy in autoimmune liver disease
Naomi Richardson, Grace Wootton, Amber Bozward, et al.
Seminars in Immunopathology (2022) Vol. 44, Iss. 4, pp. 461-474
Open Access | Times Cited: 36
Emerging mechanisms and applications of low-dose IL-2 therapy in autoimmunity
Pengcheng Zhou
Cytokine & Growth Factor Reviews (2022) Vol. 67, pp. 80-88
Closed Access | Times Cited: 34
Regulatory T cells and immunoglobulin E: A new therapeutic link for autoimmunity?
Óscar Palomares, Dirk Elewaut, Peter M. Irving, et al.
Allergy (2022) Vol. 77, Iss. 11, pp. 3293-3308
Open Access | Times Cited: 33
The potential for treg-enhancing therapies in nervous system pathologies
Katherine E. Olson, R. Lee Mosley, Howard E. Gendelman
Clinical & Experimental Immunology (2022) Vol. 211, Iss. 2, pp. 108-121
Open Access | Times Cited: 32
Page 1 - Next Page

Scroll to top